Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

RNAseq comparison between ovarian cancer cells re-expressing LACTB and primary ovarian cells

ABSTRACT: RNAseq comparison between ovarian cancer cells re-expressing LACTB and primary ovarian cells

PROVIDER: PRJEB55652 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Similar Datasets

RNAseq comparison between ovarian cancer cells re-expressing LACTB and primary ovarian cells

Project description:Describing the LACTB tumor suppressor activity in ovarian cancer cells

2022-10-02 | E-MTAB-12053 | biostudies-arrayexpress

As an unfavorable prognostic factor, LACTB promotes metastasis of nasopharyngeal carcinoma via activation of ERBB3/EGFR-ERK signaling

Project description:Nasopharyngeal carcinoma (NPC) is a malignant tumor originating from the nasopharyngeal epithelium and has the highest metastatic rate among head and neck cancers, NPC metastasis has become the main cause of treatment failure. The molecular basis regulating NPC metastasis remains obscure. Here we discovered a gene named LACTB Highly expressed in NPC tissues and aimed to investigate its role and regulatory mechanism in the metastasis of NPC.LACTB was found to promote NPC cellular motility in vitro and metastasis in vivo via the activation of the ERBB3/EGFR-ERK pathway on a histone H3 depending manner. Also, the elevated expression of LACTB in the primary NPC correlated with patient poor survival, indicating LACTB as a potential prognostic predictor and an anti-metastasis therapeutic target.

2020-05-19 | GSE150761 | GEO

Chromatin Proteome of Drosophila Ovarian somatic cells

Project description:Chromatin Proteome was enriched from drosophila ovarian somatic cells using ChEP.

2021-07-02 | PXD024167 | JPOST Repository

Genomic signatures of platinum re-sensitization in ovarian cancer [RNA-Seq]

Project description:Epigenetic changes, particularly DNA methylation aberrations have been implicated in acquired resistance to platinum in ovarian cancer. A multi-institutional randomized clinical trial compared a regimen of a DNA methyl transferase (DNMT) inhibitor guadecitabine and carboplatin to physician’s choice chemotherapy for patients with recurrent platinum resistant ovarian cancer. Tumor biopsies or malignant ascites were collected at day 1 of cycle 1 (pre-guadecitabine) and after two cycles of treatment (post-decitabine). The goal of the current study was to analyze guadecitabine-induced DNA methylation and gene expression changes and correlate pretreatment levels with clinical outcomes. Epigenomic and transcriptomic profiling using the Infinium HumanMethylation450 BeadChip (HM450) and RNA sequencing revealed extensive methylation and gene expression changes induced by guadecitabine in ovarian tumors. Ninety-four gene promoters were significantly hypomethylated after treatment with guadecitabine and 949 genes were differentially expressed in pre vs. post-treatment tumors. Pathways associated with immune reactivation and DNA repair were significantly altered by guadecitabine treatment. Expression levels of 1155 genes involved in 25 networks on day 1 of cycle 1 correlated with progression free survival. Increased expression of selected genes (e.g. DOK2, miR193a) silenced through promoter methylation restored platinum sensitivity in ovarian cancer cells. Together, these results support that guadecitabine altered DNA methylation and expression of genes and gene networks correlate with re-sensitization to carboplatin in ovarian cancer patients.

2018-06-05 | GSE102118 | GEO

Next Generation Sequencing Facilitates Quantitative Analysis of Transcriptomes of Melanoma Cell MUM2B overexpressing Empty Vector Or LACTB

Project description:Methods: mRNA profiles of MUM2B cells stably overexpressing empty vector or LACTB were generated by deep sequencing, in triplicate, using Illumina. featureCounts v1.5.0-p3 was used to count the reads numbers mapped to each gene. And then FPKM of each gene was calculated based on the length of the gene and reads count mapped to this gene. Differential expression analysis of two groups was performed using the DESeq2 R package(1.16.1). qRT–PCR validation was performed using TaqMan and SYBR Green assays

2021-07-01 | GSE162734 | GEO

Methylomic signatures of platinum re-sensitization in ovarian cancer [Illumina HumanMethylation450 BeadChip]

2018-06-05 | GSE102119 | GEO

Comparison of human primordial oocyte follicles to ovarian somatic cells

Project description:Analysis primordial follicle compared to ovarian somatic cells proteome in humans.

2022-05-09 | PXD025369 | Pride

Genomic and Epigenomic Signatures of Platinum Re-sensitization in ovarian cancer

Project description:Genomic and Epigenomic Signatures of Platinum Re-sensitization in ovarian cancer

| PRJNA396728 | ENA

Hematogenous metastasis of ovarian cancer: Re-thinking mode of spread

Project description:Ovarian cancer has a clear predilection for metastasis to the omentum, but the underlying mechanisms involved in ovarian cancer spread are not well understood. Here, we used a parabiosis model that demonstrates preferential hematogenous metastasis of ovarian cancer to the omentum. Our studies revealed that the ErbB3-neuregulin1 (NRG1) axis is a dominant pathway responsible for hematogenous omental metastasis. Elevated levels of ErbB3 in ovarian cancer cells and NRG1 in the omentum allowed for tumor cell localization and growth in the omentum. Depletion of ErbB3 in ovarian cancer substantially impaired omental metastasis. Our results highlight hematogenous metastasis as a previously under-recognized mode of ovarian cancer metastasis. These findings have implications for designing new strategies aimed at preventing and treating ovarian cancer metastasis.

2014-07-14 | GSE52999 | GEO

Suclg2 maintains the tolerogenic function of regulatory dendritic cells by suppressing Lactb succinylation

Project description:Suclg2 maintains the tolerogenic function of regulatory dendritic cells by suppressing Lactb succinylation

| PRJNA906581 | ENA